The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole

被引：0
|
作者：
Bekkers, CHJ
Touw, DJ
Lamers, CBHW
Geus, WP
机构：
[1] Hague Cent Pharm, The Hague, Netherlands
[2] Leiden Univ, Med Ctr, NL-2300 RA Leiden, Netherlands
[3] Leyenburg Hosp, The Hague, Netherlands
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2002年 / 54卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：553 / 553
页数：1
相关论文
共 50 条
  • [1] A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism
    Hunfeld, N. G.
    Touw, D. J.
    Mathot, R. A.
    Mulder, P. G. H.
    van Schaik, R. H.
    Kuipers, E. J.
    Kooiman, J. C.
    Geus, W. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 31 (01) : 150 - 159
  • [2] A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism
    Hunfeld, N. G.
    Touw, D. J.
    Mathot, R. A.
    van Schaik, R. H.
    Kuipers, E. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (07) : 810 - 818
  • [3] Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19
    Yu, KS
    Yim, DS
    Cho, JY
    Park, SS
    Park, JY
    Lee, KH
    Jang, IJ
    Yi, SY
    Bae, KS
    Shin, SG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (04) : 266 - 273
  • [4] Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
    Katsuki, H
    Nakamura, C
    Arimori, K
    Fujiyama, S
    Nakano, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (05) : 391 - 396
  • [5] Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
    H. Katsuki
    C. Nakamura
    K. Arimori
    S. Fujiyama
    M. Nakano
    European Journal of Clinical Pharmacology, 1997, 52 : 391 - 396
  • [6] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people
    Hu, Xiang-Peng
    Xu, Jian-Ming
    Hu, Yong-Mei
    Mei, Qiao
    Xu, Xin-Hua
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (05) : 517 - 524
  • [7] EFFECTS OF CYP2C19 HAPLOTYPE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF OMEPRAZOLE
    Bae, J. W.
    Choi, C., I
    Kim, M. J.
    Jang, C. G.
    Lee, S. Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 79 - 80
  • [8] Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes
    Saito, M
    Yasui-Furukori, N
    Uno, T
    Takahata, T
    Sugawara, K
    Munakata, A
    Tateishi, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (03) : 302 - 309
  • [9] Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes
    Yasui-Furukori, N
    Saito, M
    Uno, T
    Takahata, T
    Sugawara, K
    Tateishi, T
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (11): : 1223 - 1229
  • [10] Misinterpretation of the acid-inhibitory effect of PPIs in Western populations due to CYP2C19 genotype?
    Hunfeld, N. G.
    Graatsma, B. H.
    Kuipers, E. J.
    Geus, W. P.
    GASTROENTEROLOGY, 2006, 130 (04) : A301 - A302
12345